Quarterly report [Sections 13 or 15(d)]

Schedule of Reconciliation Consolidated Net Loss (Details)

v3.26.1
Schedule of Reconciliation Consolidated Net Loss (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Total Sales
Total Cost of Sales
Gross Profit
Total Administrative Expenses 1,002,949 894,297 2,069,599 1,735,982
Total Research and Development Expenses 236,133 873,472 746,667 2,418,985
Total Stock Based Compensation 2,373,655 104,854 2,432,261 189,490
Total Franchise Tax Expense 219,403
Total Segment Net Loss 3,612,737 1,872,623 5,467,930 4,344,457
Adjustments and Reconciling Items        
Total Interest and Dividend Income 100,625 57,575 171,965 120,087
Total Gain (Loss) on Sales of Marketable Securities 19,459 31,241 2,176
Total Unrealized Gain (Loss) on Marketable Securities (26,584) (147) (7,290) (1,744)
Total Change in Fair Value of Derivative Liabilities 81,000 19,000 591,000 1,303,000
Total Impairment of Technology License (3,177,999) (3,177,999)
Total Adjustments and Reconciling Items (3,003,499) 76,428 (2,391,083) 1,423,519
Consolidated Net Loss (6,616,236) (1,796,195) (7,859,013) (2,920,938)
Pharmaceuticals [Member]        
Segment Reporting [Line Items]        
Total Sales
Total Cost of Sales
Total Administrative Expenses 100,295 894,297 206,960 1,735,982
Total Research and Development Expenses 5,150 873,472 (18,948) 2,418,985
Total Stock Based Compensation 104,854 189,490
Total Franchise Tax Expense 21,940
Total Segment Net Loss 105,445 1,872,623 209,952 4,344,457
Adjustments and Reconciling Items        
Total Interest and Dividend Income 57,575 120,087
Total Gain (Loss) on Sales of Marketable Securities 2,176
Total Unrealized Gain (Loss) on Marketable Securities (147) (1,744)
Total Change in Fair Value of Derivative Liabilities 19,000 1,303,000
Total Impairment of Technology License
Total Adjustments and Reconciling Items 76,428 1,423,519
Consolidated Net Loss (105,445) (1,796,195) (209,952) (2,920,938)
Computing Technology [Member]        
Segment Reporting [Line Items]        
Total Sales
Total Cost of Sales
Total Administrative Expenses 902,654 1,862,639
Total Research and Development Expenses 230,983 765,615
Total Stock Based Compensation 2,373,655 2,432,261
Total Franchise Tax Expense 197,463
Total Segment Net Loss 3,507,292 5,257,978
Adjustments and Reconciling Items        
Total Interest and Dividend Income 100,625 171,965
Total Gain (Loss) on Sales of Marketable Securities 19,459 31,241
Total Unrealized Gain (Loss) on Marketable Securities (26,584) (7,290)
Total Change in Fair Value of Derivative Liabilities 81,000 591,000
Total Impairment of Technology License (3,177,999) (3,177,999)
Total Adjustments and Reconciling Items (3,003,499) (2,391,083)
Consolidated Net Loss $ (6,510,791) $ (7,649,061)